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ABSTRACT
The complex of the yeast Lsm1p-7p proteins with
Pat1p is an important mRNA decay factor that is
involved in translational shutdown of deadenylated
mRNAs and thus prepares these mRNAs for degrad-
ation. While the Lsm proteins are highly conserved,
there is no unique mammalian homolog of Pat1p. To
identify proteins that interact with human LSm1, we
developed a novel immunoprecipitation technique
that yields virtually pure immunocomplexes. Mass-
spec analysis therefore identifies mostly true posi-
tives, avoiding tedious functional screening. The
method unambiguously identified the Pat1p
homolog in HeLa cells, Pat1b. When targeted to a
reporter mRNA, Pat1b represses gene expression
by inducing deadenylation of the mRNAs. This dem-
onstrates that Pat1b, unlike yPat1p, acts as an
mRNA-specific deadenylation factor, highlighting
the emerging importance of deadenylation in the
mRNA regulation of higher eukaryotes.
INTRODUCTION
mRNA degradation is a crucial part of the regulation of
gene expression, as it limits the amount of protein that can
be produced from a given mRNA. The process has been
elucidated to considerable detail in yeast. In short, mRNA
degradation starts with deadenylation which is either
followed by exonucleolytic digestion from the 30-end of
the mRNA or, more important for gene regulation,
causes decapping of the transcript with subsequent
exonucleolytic digestion from the 50-end. Decapping is
catalyzed by Dcp1p/Dcp2p, which requires a series of aux-
iliary factors for full activity, such as Dhh1p, Pat1p and
the LSm proteins Lsm1p to LSm7p. These factors bind to
the mRNA prior to decapping. Pat1p and the LSm
proteins form a complex (1,2) that also co-puriﬁes with
the 50-exonuclease Xrn1p (1), even though this enzyme
becomes active only after decapping. Both Pat1p and the
LSm proteins bind to the target mRNA. The LSm
proteins are characterized by the presence of an
oligo(U)-speciﬁc RNA-binding domain (3), and Pat1p,
even though it does not have a recognizable RNA-
binding domain (nor any other identiﬁable domain), also
binds to RNA homopolymers with a preference for
poly(U) (4). In vitro, the complex preferably binds to
mRNAs with a short poly(A) tail (5) suggesting that the
complex enters mRNPs after deadenylation. Indeed, the
LSm1p to 7p proteins associate preferentially with
deadenylated mRNAs in vivo (6). Importantly, Pat1p
acts as a translational repressor (7). mRNA translation
and degradation via the decapping pathway generally
compete with each other [(7), but see also (8)]. Since the
Lsm/Pat1p complex does not interact with the decapping
enzyme, it is assumed that the Lsm proteins and Pat1p
prepare the deadenylated mRNAs for degradation by
shifting the equilibrium towards translation arrest and
thus facilitating the decapping reaction.
Less is known about mRNA degradation in higher eu-
karyotes, but the key players are well conserved (9), and
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deadenylation and proceed with decapping and 50!30 di-
gestion (10–14). mRNA degradation in higher eukaryotes
thus follows the same basic mechanism outlined above.
All components of the decapping-degradation
pathway—auxiliary factors, decapping enzyme and
50-exonuclease—co-localize in cytoplasmic foci called
P bodies (PBs), where mRNAs can actually be degraded
in yeast (15) and mammalian cells (16,17). In addition,
PBs contain the machineries for other mRNA silencing
pathways such as non-sense-mediated decay (18,19) and
miRNA-mediated silencing (20–22). PBs can also serve as
a storage point for silenced mRNAs, which can resume
translation after leaving the bodies (23). The generally
accepted function of the PBs is to enforce translational
silencing by sequestering the mRNPs from the pool of
soluble ribosomes/translation factors; the forces that
keep the PBs together are less well understood. The
current model predicts that translationally silent mRNPs
have the propensity to coalesce into the P bodies because
they are decorated with protein domains that aggregate
via homomeric interactions (24). LSm4p and the
enhancer of decapping Edc3p serve this role (25–27),
and the responsible domain in Lsm4p is the Gln/
Asn-rich carboxy terminus (26,27). A similar domain is
found in various other PB factors including Pat1p (27).
While many of the mRNA-decay factors—in particular,
the Lsm proteins—are well conserved throughout evolu-
tion, the functional homolog of Pat1p in mammals has not
been characterized. Two proteins have been proposed
based on a weak homology in the C-terminal half (four
regions with a total of 13 invariant amino acids) (7,28).
Using a novel immunoprecipitation technique, we now
unambiguously identify one of the two as the functional
Pat1p homolog in HeLa cells. The protein strongly inter-
acts with LSm1, and localizes to PB-like structures even in
the absence of functional PBs, presumably due to a Gln/
Asn-rich domain. But here, the similarities with yeast
Pat1p end: instead of being a general mRNA decay
factor, it affects speciﬁc mRNAs, and instead of function-
ing on deadenylated mRNAs, it induces deadenylation.
Human Pat1b thus is a novel factor that regulates the
expression of speciﬁc mRNAs by modulating the length
of their poly(A) tails.
MATERIAL AND METHODS
Antibodies
Anti-LSm1 (29), anti-SF3a120 and anti-SF3b155 (30)
were polyclonal antibodies raised against peptides
derived from the respective protein sequences. They were
afﬁnity-puriﬁed on a Sulfolink column (Pierce) contain-
ing the respective immobilized peptide. The Y12 monoclo-
nal antibody (31) was used directly as a hybridoma
supernatant. Polyclonal antibodies directed against
DDX6 were from Bethyl Laboratories (TX, USA). For
the description of the Pat1b antibodies, see
Supplementary data.
The adaptor protein and the double puriﬁcation procedure
A fragment encoding a calmodulin-binding peptide
(CaM-BP) and a double copy of the IgG-binding
domain (IGB) was ampliﬁed from plasmid pBS1479 (32)
and fused with the Strep tag (DWSHPQFEK) at its
N-terminus. The resulting fragment was cloned into the
NcoI/HindIII sites of the pET-M11 vector (EMBL
Heidelberg), further adding a His6 tag. The plasmid
sequence was veriﬁed by DNA sequencing. The plasmid
was introduced into BL21/pLysS cells, and synthesis of
the adaptor protein was induced by addition of 0.4mM
IPTG and incubation for 4h at 37 C. The cells were lysed
and the protein was puriﬁed by nickel chromatography
according to standard procedures.
Of calmodulin-coated beads, 0.2ml were incubated for
30min at 4 C with 20mg of adaptor protein in 2ml of
CaM-binding buffer (10mM Tris–HCl pH 8.0; 150mM
NaCl, 1mM MgCl2, 1mM imidazole, 2mM CaCl2,
0.1% Triton, 10mM b-mercaptoethanol). The beads
were washed three times with 1ml of CaM-binding
buffer, and then antibodies were added in 2ml of
CaM-binding buffer. The beads were washed as before.
For each precipitation, 1ml of nuclear extract ( 5mgof
total protein) or 4ml of cytoplasmic extract ( 14mg of
total protein) was diluted to 10ml with CaM-binding
buffer and cleared by centrifugation at 10000g for
15min. The extract was added to the beads and incubated
for 1h at 4 C. The beads were washed three times with
5ml CaM-binding buffer and then eluted with
CaM-elution buffer (10 Tris–HCl pH 8.0; 150mM NaCl,
1mM MgCl2, 1mM Imidazole, 20mM EGTA, 0.1%
Triton, 10mM b-mercaptoethanol) in ﬁve 0.2-ml frac-
tions. Fractions 2–4, containing most of the eluted
protein, were pooled, diluted to 2ml with Strep-binding
buffer (20mM Tris–HCl pH 8.0; 150mM NaCl, 1.5mM
MgCl2, 0.1% Triton) and applied to 0.2ml of
streptactin-coated beads (Qiagen). The suspensions were
incubated for 1h at 4 C, and then the beads were washed
three times with Strep-binding buffer. The puriﬁed
complexes were eluted with Strep-elution buffer (20mM
Tris–HCl pH 8.0; 150mM NaCl, 1.5mM MgCl2, 0.1%
Triton, 2mM desthiobiotin) in ﬁve 0.2-ml fractions.
Proteins were recovered by acetone precipitation,
fractionated by SDS–PAGE and visualized by SYPRO
Ruby staining.
Mass spectrometry
Visible bands from silver stained gels were cut out and
proteins were digested in-gel with trypsin as described
(33). Extracted peptides were sequenced by LC-coupled
tandem MS on a Q-ToF (Ultima, Waters) and product
ion spectra were searched for protein identiﬁcation
against NCBInr database by using MASCOT as search
engine (described in detail at ref. 34).
Immunoprecipitation
Nearly conﬂuent 100-mm dishes of HeLa SS6 cells were
rinsed with PBS, scraped into 1ml of lysis buffer (20mM
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0.5mM DTT, 0.2mM PMSF), and centrifuged for
15min at 13000g at 4 C. Of supernatants, 300ml were
added to proteinA beads containing the respective
antibodies and blocked in 1% BSA in PBS. The beads
were washed with IP buffer (20mM Tris–Cl pH 8.0,
300mM NaCl, 0.1% Triton X-100), and bound proteins
were eluted by boiling with SDS-PAGE loading buffer.
GST pull-downs
LSm1 or the mutant lacking the last 33 amino acids were
cloned into the NcoI and KpnI sites of the pET M30
vector (EMBL protein expression group). Pat1b fragments
from amino acid 381 or 561, respectively, to the
C-terminus were cloned into the NcoI and KpnI sites of
the pET M11 vector. All peptides were expressed in BL21
by induction with 0.4mM IPTG at 37 C. The Pat1b
peptides were puriﬁed by Ni afﬁnity chromatography.
LSm1 proteins were immobilized from the crude bacterial
lysate on 10ml glutathione beads (GE healthcare). The
beads were washed with precipitation buffer (20mM
Tris–HCl pH 8; 50mM NaCl; 0.05% NP-40), incubated
with Pat1b peptides for 30min at 4 C, washed again with
the same buffer, and eluted by boiling with SDS buffer.
Eluted proteins were fractionated by SDS–PAGE and
visualized by Coomassie Blue staining.
Cell transfection and immunoﬂuorescence
The entire Pat1b ORF (according to NCBI genebank
entry AL831992) was cloned into the XhoI and SacII
sites of pEGFP-C1 (Clonetech). COS-7 cells were trans-
fected with the plasmid diluted 1:4 with an empty
pBluescript vector, ﬁxed 16h after transfection, and
immunostained as indicated, using Cy3-conjugated
anti-rabbit IgG secondary antibodies (GE Healthcare).
Pictures were taken with a 60 /1.40 oil immersion object-
ive on a Nikon confocal microscope. For statistical
analysis, wide-ﬁeld micrographs were taken with a 60 /
1.35 objective (Olympus), and P bodies were automatically
counted using the ‘analyze particles’ algorithm of the
ImageJ package (National Institutes of Health; particles
with an area of 0.1–1.0mm
2 were considered).
For Pat1b knock-downs, 5 10
6 HeLa SS6 cells in
250ml Mirus Ingenio solution were electroporated at
260 V/960mF with 200pmol siRNA against Pat1b or
with the same amount of control siRNAs directed
against the GL2 luciferase. The Pat1b siRNAs were a
mixture of three ‘DsiRNA’ (IDT) targeted against pos-
itions 2284–2308, 2781–2804 and 2875–2899, respectively
(numeration according to National Institutes of Health
genebank entry NM_152716). Cells were distributed on
three 10-cm dishes, and cultured for 72h. Cells were har-
vested with a cell scraper; From a part, the RNA was
isolated (see below), from another aliquot, the proteins
were extracted by lysis in (20mM Tris–Cl pH 8, 500mM
NaCl, 0.5% NP-40, 0.2mM PMSF) and analyzed by
western blotting.
MS2 tethering and luciferase assays
The MS2 RNA-binding module was inserted between the
GFP and the Pat1b part of the plasmid described earlier.
pcLuc MS2x9 was constructed by sub-cloning a fragment
of pT7-Luc MS2x9, which contains the luciferase ORF
and downstream nine MS2-binding sites (35) into the
BglII and EcoRI sites of pcDNA 3 (Invitrogen). The
DNA constructs have all been sequenced before usage.
COS-7 cells were transfected with a mixture of pcLuc
MS2x9, a renilla luciferase control (pRL-tk, Promega),
and the GFP-Pat1b plasmid with or without the MS2
module. Cells were harvested 24h after transfection, and
luciferase activity was determined using the appropriate
kit (Promega) as detailed by the manufacturer.
Isolation and analysis of RNA
Total RNA was isolated from the equivalent of a 60-mm
dish of HeLa or COS-7 cells using the RNeasy kit
(Qiagen). If the cells were transfected with luciferase
plasmids, the RNA was digested with RQ1 DNase
(Promega) and repuriﬁed by LiCl precipitation. Plasmid
contaminations thus contributed <5% to the total signal
in qPCR, as gauged by the control omitting reverse
transcriptase.
qPCRs were performed after reverse transcription with
M-MLV reverse transcriptase (Invitrogen) using the
SYBR Green kit and the LC480 LightCycler (both
Roche). The ampliﬁcation efﬁciency (AE) of each
amplicon was deduced from serial dilution experiments.
The RNA quantities relative to the respective con-
trol were calculated from the crossing points Cp and
the predetermined AE: [RNA] AE
 Cp, with
Cp=Cpunknown   Cpcontrol.
The poly(A)-length test (PAT) was performed as
described (36). Brieﬂy, a tag was added to the mRNAs
(1mg of total RNA) by annealing them to the DNA
oligo (GCTTCAGATCAAGGTGACCTTTTTTTT
TTTT, blocked at its 30-end by aminohexyl) and extending
their 30-ends using Klenow enyme. The tagged RNAs were
retrotranscribed at 48 C using superscript III reverse tran-
scriptase (Invitrogen) and GCTTCAGATCAAGGTGAC
CTTTT as a primer. The 30-end was then ampliﬁed using a
gene-speciﬁc primer and the reverse transcription primer.
To generate deadenylated controls, 10mg total RNA were
digested with 1.5mg oligo(dT)15 and 1.25U RNaseH
(Promega). The RNA was re-isolated and quantiﬁed
prior to the PAT assay. For the graphical representation
of the poly(A) length distribution, each lane proﬁle was
digitalized. The DNA length corresponding to each pixel
was estimated by an exponential function, which was
calculated from the DNA markers on the same gel using
the Imagequant TL software (GE healthcare). The crude
intensities were divided by the DNA length to normalize
for the effect that ethidium-bromide staining is relative not
to the number of DNA molecules, but to the mass of the
DNA. The highest value in each lane was then arbitrarily
set to 100, and plotted against the poly(A) length, as
deduced from the estimated DNA length and the length
of the minimal PCR product.
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A novel immunoafﬁnity puriﬁcation strategy identiﬁes
the human homolog of Pat1p
Immunoprecipitations are routinely plagued by signiﬁcant
background precipitation that leads to high numbers of
false-positive identiﬁcations in mass spectrometry (MS)
(see, for example, the gel in Supplementary Figure S1).
To avoid the problem, we devised a double-afﬁnity
strategy to purify the immunocomplexes (Figure 1). In
brief, the antibodies are immobilized on calmodulin
beads via an artiﬁcial adaptor. The antibodies and
bound antigen complexes can thus be recovered under
native conditions, and are re-puriﬁed using the strep tag
that is also present in the adaptor. The strategy was
validated by puriﬁcation of previously characterized
RNP complexes from HeLa nuclear extracts. First, we
puriﬁed the 17S U2 snRNP, which is part of the
spliceosome, targeting the SF3a120 and SF3b155
subunits of the complex (30). The intermediate step after
EGTA elution from the calmodulin beads does not sufﬁ-
ciently enrich the SF3 complexes. In fact, many proteins
are also observed in the mock puriﬁcation that was
performed in the presence of the adaptor, but without
antibodies, and only the IgG heavy chains are visibly
enriched (Figure 2, compare lanes 2 and 3 with lane 1).
The second round of puriﬁcation, in contrast, yielded a
very clear pattern with only few visible bands in the mock
control (lane 4). Bands not detected in the control were
thus attributed to speciﬁc binding; these were cut out, and
the proteins present in the bands were identiﬁed by MS.
The main protein component (as judged by the number of
peptides identiﬁed, see Supplementary Table S1) of each
band is indicated in Figure 2. Each band corresponds to a
known component of the 17S U2 snRNP. Few additional
proteins were identiﬁed in the bands, and they are listed in
Supplementary Table S1. Most of them are also part of
the SF3 complexes, and only the SF3a120 band in lane 6
contains two proteins that were not previously described
as components of the 17S U2 snRNP and that therefore
may represent contaminations. As judged by the number
of identiﬁed peptides, these presumptive contaminations
can be considered to be minor. The method thus is well
suited to unambiguously identify proteins that are
co-puriﬁed with the a-SF3b120 and a-SF3b155 antibodies
and to distinguish these from residual contamination.
Having validated the method, it was next used to char-
acterize the cytoplasmic Sm and like-Sm (LSm)
complexes. The seven Sm proteins form the core of the
spliceosomal snRNPs; they assemble on the snRNAs in
the cytoplasm and are then imported into the nucleus. We
used a monoclonal antibody, Y12, that preferentially rec-
ognizes native assembled Sm proteins (37) to purify the
Sm complexes from HeLa cytoplasmic extracts, with the
aim to gain further insights on the cytoplasmic phase of
the Sm complex. The result of the puriﬁcation is shown in
Figure 2, lane 9: several proteins speciﬁcally
co-precipitated with the Sm proteins, but not the control
(lane 7). All proteins belong to the known nuclear snRNP
complexes U1 (U1-A), U2 (U2-A0) and U5 (220, 200, 116
and 102K). Again, the preparation was very clean, as only
a few additional proteins were identiﬁed underneath the
main components of the bands (Supplementary Table S1).
Most can be explained by the presence of nuclear Sm
snRNPs U1 (U1-70K), U2 (SF3b14) and U4/U6 (LSm3
and hPrp24). LSm10 is part of the Sm complex found on
U7 snRNA, which, although divergent from the canonical
Sm core snRNP, nevertheless binds to anti-Sm type
antibodies (38). In summary, the major proteins and
most of the minor proteins identiﬁed in each band are
known components of the nuclear snRNPs, and we
conclude that we have indeed puriﬁed nuclear snRNPs
from the cytoplasmic extract, probably due to the
presence of mitotic cells that lack a nuclear compartment,
and/or owed to leaking of the nuclei during the extraction
procedure. Nevertheless, the detection of a nuclear con-
tamination in the cytoplasm demonstrates the good yield
that can be obtained with this technique. The high purity
is again underlined by the fact that the major protein in
each band is a known snRNP protein; the only exception
is the Grb10-interacting protein. Since this protein is also
co-puriﬁed with LSm1, it may be a contaminant that gen-
erally co-puriﬁes due to the particular steps of this
protocol (‘Discussion’ section).
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Figure 1. Outline of the tandem-afﬁnity-immunopuriﬁcation strategy.
An artiﬁcial adaptor protein combines an IGB with a
calmodulin-binding peptide (C) and a strep tag (S). The adaptor is
used to immobilize antibodies on calmodulin beads, which are then
incubated with extracts containing the antigen. Immunocomplexes are
recovered by native elution with EGTA and are re-puriﬁed on
Streptactin beads.
638 Nucleic Acids Research, 2011,Vol. 39,No. 2Finally, the Sm-like protein LSm1 was puriﬁed from
HeLa cytoplasmic extracts. So far, LSm1 is known only
to bind to the LSm proteins LSm 2–7, and its yeast coun-
terpart binds to the degradation factor Pat1p, the func-
tional mammalian homolog of which remains to be
identiﬁed. In this case, a lot of antibody was used, and
IgGs or fragments thereof overshadow parts of the gel
(‘Discussion’ section). Several gel slices (indicated by as-
terisks in Figure 2, lane 8) therefore yielded only IgG se-
quences. Several bands in the lower part of the gel were
identiﬁed as the antigen LSm1 and other members of the
LSm family, conﬁrming that they form stable complexes
with LSm1. Two bands are speciﬁcally enriched in the
upper part of the gel: one corresponds to the
Grb10-interacting protein (see above), while the other
identiﬁed one of the two Pat1p homologs present in the
human database. In the following, we call this protein
Pat1b—in Xenopus, the other homolog is expressed ﬁrst
during development and therefore gets the letter ‘a’ (39).
Characterization of Pat1b
To verify the LSm1-Pat1b interaction, anti-Pat1b
antibodies were generated (described in Supplementary
Figure S2) to co-precipitate LSm1 from COS-7 cell
lysates. As shown in Figure 3A, both the anti-LSm1 and
the new anti-Pat1b antibodies efﬁciently precipitate their
own antigen (lane 3, top panel, and lane 4, bottom). In
addition, LSm1 efﬁciently co-precipitates with the
anti-Pat1b antibodies, but not with mock IgGs (lanes 3
and 2, respectively). Likewise, Pat1b co-precipitates with
anti-LSm1 antibodies (lanes 4 and 2). In order to deter-
mine if the interaction depends on the formation of
mRNPs or P bodies, the immunoprecipitations were
repeated in the presence of RNase (lanes 7 and 8), or
from extracts of cells that were treated with
cyclohexamide, which strongly reduces the number of P
bodies (see Figure 4, and refs 16 and 17). Neither of the
two treatments affects the efﬁciency of LSm1–Pat1b
co-precipitation (lanes 7, 8 and 11, 12). To verify if the
interaction occurs via direct binding of the two proteins,
we reconstituted the complex from recombinant proteins
expressed in Escherichia coli. Full-length Pat1b proved
impossible to express in a soluble form. We therefore ex-
pressed two fragments that contain the central, highly
conserved domain and the C terminus, but has the
putative aggregation domain in the N terminus deleted
(see below), or only the C terminus. Binding of these frag-
ments was tested to LSm1 full length immobilized to
mock
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Figure 2. Results of the tandem-afﬁnity immunopuriﬁcation. The procedure was carried out using a-SF3a120 (lane 2), a-SF3b155 (lane 3) or no
antibodies (lane 1). Proteins were recovered by acetone precipitation from 10% of the calmodulin eluates, fractionated by SDS–PAGE and stained
with SYPRO Ruby. The remainder was further puriﬁed on streptactin beads, eluted, and stained in a similar way (lanes 4–6). Bands that were excised
for MS are indicated by arrows showing the major protein component found in the respective band. Double puriﬁcation of the LSm1 and Sm
complexes from HeLa cytoplasmic extracts is shown in lanes 7–9. As before, the protein composition of the ﬁnal eluate is shown for the precipitation
with the a-LSm1 polyclonal antibody (lane 8), the Y12 a-Sm monoclonal antibody (lane 9) or no antibodies (lane 7). Regions in lane 8 marked by
asterisks were found to contain only IgGs or fragments thereof.
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(deletion of 33 amino acids from the C terminus). Pat1b
N binds to both LSm1 peptides, but not an unrelated
protein (compare Figure 3B, lanes 3 and 4 with 2; the
weaker precipitation with full-length LSm1 should not
be overvalued, since there was less GST fusion protein
immobilized in this assay). This demonstrates that Pat1b
directly binds to LSm1, forming contacts predominantly
with the Sm domain. The C terminus of Pat1b is also
sufﬁcient for this interaction, albeit to a lesser extent
when compared to the input (Figure 3B, lanes 5, 7 and
8). We conclude that Pat1b and LSm1 bind to each other
via protein–protein interactions that are independent of
P-body formation.
As an LSm1-interacting protein, Pat1b is expected to
localize to the P bodies (PBs, 29). In fact, COS-7 cells
all exhibited bright cytoplasmic foci in an anti-Pat1b im-
munoﬂuorescence (Figure 4A). As observed for other
P body markers (16,17), arrest of protein translation by
cycloheximide greatly reduces the number of
Pat1b-positive P bodies (from an average of 10.5 per cell
to 1.5, Figure 4A), indicating that these foci are bona ﬁde
P bodies. To visualize LSm1-Pat1b co-localization, a
GFP-Pat1b fusion protein was expressed in COS-7 cells
and counter stained with anti-LSm1 antibodies.
Interestingly, GFP-Pat1b forms many more foci than en-
dogenous Pat1b or LSm1 (an average of 29.5 versus 10.5
and 8.4, respectively: Figure 4B, upper row). Endogenous
LSm1 is found in GFP-Pat1b-positive PBs (which thus
appear yellow in the merged picture, see in particular the
cell on the upper right), but the excess of GFP-Pat1b PBs
does not contain detectable levels of endogenous LSm1
and thus appears green in the overlay image, indicating
that most GFP-Pat1b foci do not represent bona ﬁde PBs.
This notion is supported by the ﬁnding that cycloheximide
treatment disperses the LSm1, but not the GFP-Pat1b foci
(see Figure 4B, lower row, and the statistical evaluation at
the bottom). Very much the same picture is observed when
counterstaining GFP-Pat1b-transfected cells with the
P-body marker Ddx6/RCK (Supplementary Figure S3).
We therefore conclude that Pat1b can form P body-like
foci in the cytoplasm that are independent of the presence
of natural P bodies, as they do not dissolve with
cycloheximide, and do not contain endogenous P body
markers. These aggregates were observed despite the fact
that we limited expression of GFP-Pat1b by diluting the
plasmid (‘Materials and Methods’ section). It is probably
no coincidence that Pat1b can form PB-like structures, as
the protein contains a Q/N-rich putative aggregation
domain in its N-terminal half (data not shown; see also
‘Discussion’ section).
Pat1b represses translation by inducing deadenylation
and degradation of the target mRNA
To elucidate the function of Pat1b, we used the MS2
protein to tether Pat1b to a ﬁreﬂy luciferase reporter
15
25
70
100
130
kDa
kDa kDa
Pat1b
LSm1
input
mock IgG
α-Pat1b
α-LSm1
input
mock IgG
α-Pat1b
α-hLSm1
input
input
GST-DCoH
GST-LSm1ΔC
GST-LSm1
input
GST-DCoH
GST-LSm1ΔC
GST-LSm1
mock IgG
α-Pat1b
α-LSm1
untreated RNase CHX
8 7 6 5 4 3 2 1
1 2 3 4 5 6 7 8 9 10 11 12
70
55
45
35
70
55
45
35
His-Pat1b(C)
GST proteins
His-Pat1b(ΔN)
GST proteins
A
B
Figure 3. LSm1 co-precipitates with Pat1b independently of RNA or PBs. (A) COS-7 cell lysates were immunoprecipitated with mock IgGs (lanes 2,
6, 10), with anti-Pat1b antibodies (lanes 3, 7, 11) or with anti-LSm1 antibodies (lanes 4, 8, 12). Co-precipitating proteins were fractionated by SDS–
PAGE and blotted. The upper part of the blot was immunostained for Pat1b, the lower part for LSm1. Of the respective input, 10% was loaded in
lanes 1, 5 and 9. Lanes 1–4 show the experiment performed with untreated lysates. In lanes 5–8, 20mg/ml RNase A and 50 U/ml RNase T1 was
added to the cell lysate before immunoprecipitation, and in lanes 9–12, cells were treated with 25mg/ml cycloheximide for 30min at 37 C prior to
lysis. The migration of molecular weight markers is indicated on the left, and the position of the proteins of interest on the right. (B) GST-DCoH (an
unrelated protein encoded by the original pET M30 plasmid; lanes 2 and 6), GST-LSm1 C (lanes 3 and 7) as well as GST-LSm1 (lanes 4 and 8)
was immobilized to glutathione beads, and incubated with Pat1b N (2–4), or with the Pat1b C-terminal domain (6–8). Proteins bound to the beads
were eluted and fractionated by SDS–PAGE. Shown is the Coomassie-stained gel; lanes 1 and 5 show the input Pat1b fragments.
640 Nucleic Acids Research, 2011,Vol. 39,No. 2that contains nine MS2-binding sites in its 30-UTR. COS-7
cells were transfected with a mixture of the reporter
plasmid, a Renilla luciferase cDNA that lacks
MS2-binding sites, and the Pat1b constructs with or
without the MS2 fusion. After 24h, the cells were lysed
and the activity of the ﬁreﬂy luciferase relative to the
Renilla enzyme was determined. As shown in Figure 5A,
targeting of Pat1b drastically lowered expression of the
ﬁreﬂy luciferase with respect to the Pat1b construct
lacking the MS2 domain (down by 61%: P<0.001;
n=14). To determine whether this is due to a destabiliza-
tion of the mRNA or to translational arrest, we measured
the mRNA levels by quantitative PCR (qPCR). The
reduced expression can be entirely explained by a
reduced abundance of the ﬁreﬂy luciferase mRNA
relative to its Renilla counterpart (Figure 5B—the
amount of mRNA is reduced by 62%: P<0.05; n=6).
This strongly suggests that the stability of the targeted
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Figure 4. Pat1b localization in PBs. (A) Endogenous hPat1 was revealed by immunostaining COS-7 with anti-hPat1 antibodies. The left micrograph
shows a representative confocal slice of control cells, the right one of cells that were treated with 25mg/ml cycloheximide (CHX) for 30min prior to
ﬁxation. The decrease in observable cytoplasmic foci (from 10.5 to 1.5, counted on 85 and 66 cells, respectively) is highly signiﬁcant (***P<0.0001,
Student’s t-test). Scale bars, 5mm. (B) COS-7 cells were transfected with GFP-Pat1b (green in the panels on the left) and immunostained for LSm1
(red in the middle panels). The upper row shows a confocal image of control cells, the lower row of cells treated with CHX. Scale bars, 5mm. The
statistical analysis is shown at the bottom: the count of GFP-Pat1b foci does not signiﬁcantly change (average of 29.5 in 44 control cells versus 43.6
in 25 CHX-treated cells; P=0.085 in Student’s t-test), while the count of LSm1 foci decreases from 8.4 to 3.5 (in 84 control and 65 treated cells;
***P<0.0001). Note that the count of LSm1-positive foci also decreases in the GFP-Pat1b-transfected cells (P<0.0002; data not shown).
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Figure 5. Pat1b down-regulates the expression of target genes by inducing deadenylation and destabilization of the mRNAs. COS-7 cells were
co-transfected with a ﬁreﬂy luciferase construct containing MS2-binding sites, Renilla luciferase control and either GFP-Pat1b or GFP-MS2-Pat1b.
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(B) The abundance of the ﬁreﬂy mRNA relative to the Renilla reporter, as determined by qPCR, with the error bar indicating the standard deviation.
(continued)
642 Nucleic Acids Research, 2011,Vol. 39,No. 2mRNA is compromized. Usually, the ﬁrst step in mRNA
decay is the shortening of the poly(A) tail. The lengths of
the poly(A) tails were measured by the tag-addition
method (36). Figure 5C shows the poly(A) length distri-
bution of the ﬁreﬂy luciferase reporter and, as a control, of
the endogenous GAPDH mRNA. The trace of the
intensities in each lane is plotted on the right of the gel
images (for their calculation, see ‘Materials and Methods’
section). Both the reporter and the control mRNA show
two broad peaks at  100 and 300–400 adenosines
(as judged from the migration of DNA markers; lanes 2
and 5), and both populations reﬂect differentially
polyadenylated mRNAs, as artiﬁcial deadenylation con-
denses both peaks into one single, sharp band migrating at
the expected height. When cells are transfected with the
targeted MS2-Pat1b construct, the ﬁreﬂy luciferase
mRNA, but not the GAPDH control, is severely
deadenylated: the peak at 350 adenosines becomes less
intense and shifts to shorter lengths, and the main peak
is shifted to <50 adenosines, suggesting that Pat1b
binding primarily induces deadenylation.
To verify this hypothesis, we performed a deadenylation
time course (Figure 5D). Synthesis of new mRNAs was
shut down by actinomycin D, and the poly(A) length dis-
tribution was monitored over 6h (Figure 5D). For the
non-targeted reporter construct (odd lanes), the distribu-
tion does not change much: only the population of
mRNAs with poly(A) tails of  100nt decreases relative
to the population with longer poly(A) tails, indicating that
the mRNAs with long poly(A) tails decay slower. In
contrast, the population with  100 A residues is much
less prominent for the reporter mRNA targeted by MS2
already at the steady state level (Figure 5D, lane 2; see also
Figure 5C). During the time course, this population
further decreases and another population with critically
short poly(A) tails (around 20nt) builds up. This shows
that upon Pat1b tethering, a step downstream of
deadenylation becomes rate limiting and therefore demon-
strates that Pat1b primarily induces a shortening of the
poly(A) tail, which then leads to the destabilization of the
mRNA. No obvious changes are observed in the mRNA
population with the long poly(A) tails, suggesting that
Pat1b targets primarily mRNAs with tails of  100 As
and/or that mRNAs with longer tails are protected, e.g.
by active translation.
Knock-down of Pat1b increases the poly(A) tail of
speciﬁc mRNAs
To see if Pat1b has a similar function under physiological
conditions, the protein was depleted by siRNA
transfection to <20% of the mock-treated levels
(Figure 6A). Three unstable mRNAs were selected,
namely cyclin D1 (ccnD1), c-fos (fos) and the
immediate-early response mRNA ier3. All three contain
characterized AU-rich elements (AREs) in their 30-UTRs.
The levels of these mRNAs were determined by qPCR.
Comparing mock-treated and Pat1b-depleted cells, the
ccnD1 mRNA tends to be more stable and therefore
more abundant, but the trend is not statistically signiﬁ-
cant. fos mRNA levels increase by 15%, and this is sig-
niﬁcant (P<0.05; n=9). The amount of the
immediate-early response mRNA ier3, instead, stays per-
fectly the same (Figure 6B). Pat1b depletion thus affects
some but not all unstable mRNAs. If Pat1b indeed
induces deadenylation, then depletion of the protein
should have parallel effects on deadenylation and
mRNA abundance. In fact, the poly(A) length distribu-
tions for the mRNAs that do not change in quantity nicely
superimpose between the mock-treated and the
Pat1b-depleted samples (Figure 6C, see the GAPDH—
used for normalization in 6B—and the ier3 and ccnD1
mRNA panels). Only the fos mRNA behaves differently
in that a population of this mRNA has critically short
poly(A) tails already in the mock-treated sample (Peak
at 25 adenosines, upper-right panel in Figure 6C). This
population decreases by  20% when Pat1b is depleted.
In summary, Pat1b depletion affects the poly(A) tail
length of only one of the instable mRNAs tested here.
That we did not ﬁnd a more striking effect may be due
to the residual Pat1b left after siRNA depletion
(Figure 6A). Alternatively, Pat1b could regulate only a
subset of mRNAs under speciﬁc physiological or develop-
mental conditions (‘Discussion’ section).
DISCUSSION
In the present study, we have identiﬁed the human
ortholog of the yeast auxiliary decapping factor Pat1p
by virtue of its interaction with LSm1, utilizing a novel
immunoafﬁnity method. Immunopuriﬁcation is a straight-
forward approach to the isolation of macromolecular
complexes, as immobilized antibodies recognize their
target with high speciﬁcity and binding strength. One of
the shortcomings of immunoprecipitation is the high level
of non-speciﬁcally bound proteins. Mass-spec analysis of
the precipitate therefore routinely identiﬁes many false
positives, and the strategy requires extensive screening of
the identiﬁed proteins, e.g. with a functional assay. To
overcome this problem, quantitative MS has been used
to measure which proteins are enriched relative to a
control precipitation (SILAC) (40). This approach is
Figure 5. Continued
*P<0.05 in Student’s t-test. The left panels of (C) show the poly(A) tests of the ﬁreﬂy luciferase (lanes 1–3) and of the endogenous GAPDH mRNA
(lanes 4–6). The sample analyzed in lanes 2 and 5 stemmed from cells transfected with GFP-Pat1b, in lanes 3 and 6 from cells expressing
GFP-MS2-Pat1b. In lanes 1 and 4, the RNA was artiﬁcially deadenylated by RNaseH digestion in the presence of oligo(dT). The length of the
poly(A) tail, as estimated from the migration of DNA markers, is indicated on the left panels. The proﬁles of lanes 1, 4 are shown in light gray, lanes
2, 5 in dark gray, and 3, 6 in black. The ordinate axes report arbitrary units of intensity, which was normalized for fragment length in order to reﬂect
molar distribution. (D) Time course of the poly(A) decay. Transfected cells were treated with actinomycin D (5mg/ml) for the indicated times, total
mRNA was isolated, and the poly(A) length of the ﬁreﬂy luciferase mRNAs was determined as in 5C. The mRNA populations containing tails of
 20 and 100 adenosines, respectively, are indicated on the right.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 643cost-intensive and limited to experimental setups that
permit isotope labelling. Moreover, without a highly
accurate MS instrument, data evaluation is rather time
consuming. Therefore, it is desirable to perform
mass-spec analysis on highly pure complexes in order to
exclude false positives in the ﬁrst place. To this end,
tagging strategies have been developed, such as the
FLAG (41), or the ‘tandem afﬁnity puriﬁcation’ tag
(32). The latter is particularly suited, as the complexes
are puriﬁed by two subsequent steps, eliminating most
of the background. Every tagging method, however, has
several disadvantages. The tag may interfere with the
function and/or interactions of the target protein. Even
when the tag does not block the function, the untagged
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Figure 6. Pat1b stabilizes the poly(A) tail of select mRNAs. HeLa cells were electroporated in the presence of siRNAs directed against the ﬁreﬂy
luciferase (GL2) or against Pat1b. After 72 h, both proteins and RNA were extracted. (A) Total proteins were separated by SDS–PAGE, transferred
onto a membrane and stained with antibodies against Pat1b (top) or against GAPDH (bottom). The band intensities were quantiﬁed, and Pat1b was
normalized ﬁrst against GAPDH, and then against the average of Pat1b in the GL2-treated extracts. The resulting Pat1b levels are indicated above
each lane. The migration of marker proteins is indicated to the right. (B) The total RNAs were reverse-transcribed and the levels of the ccnD1, fos,
and ier3 mRNAs were quantiﬁed by qPCR. Shown are the relative quantities after normalization for GAPDH mRNA and the average of the
respective mRNA levels in the GL2-treated samples. *P<0.05 in Student’s t-test (n=9). (C) Poly(A) lengths of the mRNAs encoding ccnD1 (lanes 1
to 3), fos (4–6), ier3 (7–9) and GAPDH (10–12) were determined. Lanes 2, 5, 8 and 11 show the PAT reaction for the GL2-treated sample, lanes 3, 6,
9, 12 for the Pat1b-depleted sample. Lanes 1, 4, 7 and 10 also show the Pat1b-depleted mRNA, but the RNAs were deadenylated prior to the PAT
reaction. To the right of each block, the intensity of the GL2 and Pat1b-transfected sample is displayed. The values represent arbitrary units,
normalized for the total signal of each lane.
644 Nucleic Acids Research, 2011,Vol. 39,No. 2protein is often preferentially incorporated into native
complexes, so that the endogenous copy of the gene
must be replaced or inactivated (42). Finally, the tagged
gene has to be introduced into, and expressed in, cells of
the parent organism, with all the attendant practical
difﬁculties. This can be achieved in cell culture by viral
transfection (43), but is all but impossible in a mammalian
organism yet.
We have combined the advantages of immunopur-
iﬁcation and TAP tag afﬁnity puriﬁcation by moving the
tag from the target protein to the antibody (Figure 1). The
strategy was validated with antibodies directed against
members of the spliceosomal SF3 complex (30). We
placed emphasis on the identiﬁcation of genuine complex
components with the highest possible conﬁdence; no effort
was undertaken to obtain a complete list of the proteins
that bind to our target proteins. Indeed, the puriﬁcation of
the SF3a120 and SF3b155 proteins led almost exclusively
to the identiﬁcation of components of the SF3a and SF3b
splice factors. Only one band contained, in addition to
SF3a120, minor quantities of proteins not related to SF3
(Supplementary Table S1). Thus, the two antigen proteins
were correctly and unambiguously identiﬁed as parts of
the 17S U2-splicing complex. This particle, however,
contains additional protein components that we did not
identify here that might have been, for example, hidden
under the IgG bands. Also, we did not identify all LSm
proteins known to be associated with LSm1. Sm/LSm
proteins are mostly hard to detect as they are very small
and thus yield only a limited number of useful tryptic
peptides; hLSm5has not one in the 400–2000Da range
that is typically analyzed. Our protocol can in principle
be followed for any macromolecular complex. The
amount of antibodies must be closely controlled in each
experiment: a certain excess is necessary to obtain efﬁcient
precipitation. With a large excess, however, the IgG bands
overshadow a great part of the gel (Figure 2, lane 8). If a
complete analysis were desired, the procedure could be
modiﬁed to subtract the antibodies, or to use less stringent
conditions, resulting in a bigger yield of intact complexes.
Also, the two tags employed should be modiﬁed according
to the particular needs: in brain extracts, for example,
recovery rates of the calmodulin adapter are virtually nil
(C.Mattioli and T.Achsel, unpublished data), most likely
due to the high levels of endogenous calmodulin in the
extracts. The basic outline of our method, however, will
be very useful in purifying any macromolecular complex
for which suitable antibodies are available.
When using the protocol to purify LSm1-associated
factors, we identiﬁed only two non-LSm proteins. This
again underlines the advantage of the double-puriﬁcation
method: conventional immunoprecipitation with the same
antibodies showed many bands, and virtually all are also
observed in the mock control (Supplementary Figure S1).
Of the two proteins, the ‘Grb-10 interacting protein’ was
also observed in the Y12 puriﬁcation of the snRNPs and
thus either represents a protein that always co-puriﬁes
when our method is applied to cytoplasmic extracts—it
would be the only such background protein—or it may
generally interact with complexes of the Sm/LSm family.
In support of the latter notion, the protein contains a
GYF domain. Such a domain is also found in the
snRNP protein 52K (44), and the 52K GYF domain can
interact with the Sm protein B/B’ (45). The other hit
identiﬁed one of two potential mammalian orthologs of
the yeast factor Pat1p (28). We conﬁrmed this interaction
using conventional immunoprecipitation: The protein
co-precipitates with anti-LSm1 antibodies, and the recip-
rocal precipitation also works efﬁciently (Figure 3). The
interaction of the two proteins is independent of RNA and
of P-body formation. Together with the high efﬁciency of
co-precipitation this suggests that the two proteins directly
interact with each other. The other potential homolog
(7,28) was not identiﬁed in our screen, indicating that it
is absent from or at least underrepresented in the HeLa
LSm complex. Either, the protein is not expressed in HeLa
cells, or it does not efﬁciently bind to LSm1. In favor of
the ﬁrst notion, the Xenopus ortholog of the other Pat
protein was identiﬁed as an oocyte-speciﬁc protein. It
also argues against the second idea that the central
domain that is responsible for the Pat1p-LSm1p inter-
action in yeast (4) is conserved in both mammalian Pat1
proteins (data not shown). We conclude that the main
LSm1-interacting protein in undifferentiated mammalian
cells is the factor that we have identiﬁed here, Pat1b.
As expected, endogenous Pat1b is highly concentrated
in cytoplasmic foci (Figure 4), and the co-localization of
GFP-Pat1b with LSm1 and Ddx6 identiﬁes these foci
as the P bodies (Figure 4) (28). Interestingly,
cycloheximide-induced reduction of the PBs affected
only the distribution of endogenous Pat1b; GFP-Pat1b
remained concentrated in cytoplasmic foci of similar size
and number. Since these foci are void of Lsm1 and Ddx6,
we interpret them as aggregates caused by over-expression
of the protein—even though we tried to limit the amount
of overexpressed protein. These foci tell us that Pat1b is
prone to aggregation into structures that resemble PBs.
PBs are seen as self-organized assemblies of translationally
silent mRNPs induced by self-interacting proteins on these
complexes (24). In yeast, the Gln/Asn-rich C terminus of
LSm4p has been incriminated (26,27). Several other yeast
P body factors contain domains that are strikingly rich in
glutamine and asparagine, including the Pat1p amino
terminus (27). This domain is not evolutionarily
conserved, but the amino-terminal half of Pat1b is also
rich in glutamine and asparagine: 17 amide residues in
the highest-scoring 80-mer peptide (data not shown),
against 23 in the yeast protein, and eight in an average
protein (27). It therefore appears that the driving force of
P body assembly, aggregation of Gln/Asn-rich domains,
has remained the same in yeast and man, even if the indi-
vidual domains are not conserved.
In yeast, Pat1p represses translation and induces
packaging of the mRNPs into PBs, with mRNA degrad-
ation following downstream (7). We therefore expected
that tethering of Pat1b to a reporter mRNA would
repress its expression primarily by inhibiting translation.
To our surprise, we found that the decrease in protein
expression is precisely matched by a reduction in mRNA
abundance (Figure 5A and B). Furthermore, Pat1b modu-
lates the level of mRNAs with oligo(A) tails (Figures 5C
and D, and 6C). If Pat1p enhanced degradation after
Nucleic AcidsResearch, 2011, Vol.39,No. 2 645deadenylation, its presence should decrease the
steady-state level of deadenylated mRNAs, and its
absence should increase them. The opposite was
observed (Figures 5C and 6C). Therefore, our data can
only be explained assuming that Pat1b increases the
steady-state level of mRNAs with short poly(A) tails, i.e.
it has a role in mRNA deadenylation. This notion is
strongly supported by the actinomycin D time course
that shows that in mRNAs targeted by Pat1b, a
deadenylated decay intermediate accumulates (Figure
5D). While this article was in ﬁnal preparation, a descrip-
tion of the Drosophila Pat1 homolog was published (46).
This protein associates with the Ccr4/Not deadenylase
complex, which greatly supports our hypothesis.
Although yeast Pat1p binds RNA with a preference for
poly(U) (4), the yeast factor does not speciﬁcally induce
degradation of some mRNAs, nor is it involved in speciﬁc
regulatory pathways. Assuming a similarly general
function, we tested three randomly picked unstable
mRNAs. Of these three, Pat1b depletion affected only
one, namely the fos mRNA. Both mRNA abundance
and poly(A) length distribution of the fos mRNA are
affected, even though the effect is minor in both cases:
in fact, the evident decrease in the mRNA population
with very short mRNAs (Figure 6C) should be matched
by a concomitant increase of longer tails, but this is too
small and diluted to be discerned. Thus, the small ampli-
tude of the effect suggests that the fos mRNA may even
not be the main target for Pat1b regulation. In mammals,
the best-described mRNA destabilization elements are the
AREs and miRNA-binding sites. AREs do not specify
Pat1b-mediated deadenylation, because all three mRNAs
checked here contain active AREs, but only fos mRNA
was affected by Pat1b depletion. Furthermore, the
ARE-binding TTP recruits the Ccr4/CAF1 deadenylase
to the mRNA and thereby directly induces shortening of
the poly(A) tail without the need for additional factors
such as Pat1b (47). miRNAs and the associated RISC
complex likewise associate with Ccr4/CAF1, and therefore
trigger deadenylation independently of other factors
(12,48,49). While we cannot formally rule out that Pat1b
has a mere auxiliary role in one of the two
mRNA-destabilizing pathways, we think it is much more
likely that it is involved in a third, as yet unknown
deadenylation pathway.
In conclusion, Pat1b is a deadenylating factor that acts
on speciﬁc mRNAs. Deadenylation is becoming ever more
important for gene regulation. Examples include the
miRNA pathway, the regulation of AREs by TTP (see
above), or the anti-proliferative pathway regulated by
the Tob family of proteins (50,51). Pat1b—in contrast to
what is known about its yeast counterpart—therefore has
all that it takes to be a speciﬁc regulator of gene expres-
sion. It will be interesting to see, in future experiments, in
which pathways Pat1b is involved.
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